Synlogic, Inc. (SYBX): Price and Financial Metrics

Synlogic, Inc. (SYBX): $1.91

0.04 (-2.05%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SYBX to Watchlist
Sign Up

SYBX Price/Volume Stats

Current price $1.91 52-week high $12.15
Prev. close $1.95 52-week low $1.55
Day low $1.79 Volume 56,800
Day high $1.96 Avg. volume 197,432
50-day MA $3.25 Dividend yield N/A
200-day MA $5.01 Market Cap 17.55M

SYBX Stock Price Chart Interactive Chart >

SYBX POWR Grades

  • SYBX scores best on the Growth dimension, with a Growth rank ahead of 86.34% of US stocks.
  • The strongest trend for SYBX is in Stability, which has been heading down over the past 50 days.
  • SYBX's current lowest rank is in the Stability metric (where it is better than 14.65% of US stocks).

SYBX Stock Summary

  • SYBX's price/sales ratio is 62.04; that's higher than the P/S ratio of 96.96% of US stocks.
  • Revenue growth over the past 12 months for SYNLOGIC INC comes in at -57.5%, a number that bests merely 4.02% of the US stocks we're tracking.
  • The volatility of SYNLOGIC INC's share price is greater than that of 97.84% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SYNLOGIC INC are CYCC, SEEL, SYRS, ABUS, and CRBU.
  • SYBX's SEC filings can be seen here. And to visit SYNLOGIC INC's official web site, go to www.synlogictx.com.

SYBX Valuation Summary

  • SYBX's price/sales ratio is 50; this is 2172.73% higher than that of the median Healthcare stock.
  • SYBX's EV/EBIT ratio has moved up 4.5 over the prior 100 months.

Below are key valuation metrics over time for SYBX.

Stock Date P/S P/B P/E EV/EBIT
SYBX 2023-12-29 50.0 0.8 -0.6 -0.5
SYBX 2023-12-28 44.8 0.7 -0.5 -0.4
SYBX 2023-12-27 46.6 0.8 -0.6 -0.4
SYBX 2023-12-26 50.3 0.8 -0.6 -0.5
SYBX 2023-12-22 47.2 0.8 -0.6 -0.4
SYBX 2023-12-21 39.3 0.6 -0.5 -0.3

SYBX Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -119.89%.
  • Its 2 year net cashflow from operations growth rate is now at 28.24%.
  • Its 2 year net income to common stockholders growth rate is now at -12.96%.
Over the past 67 months, SYBX's revenue has gone up $1,666,000.

The table below shows SYBX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.666 -57.555 -64.54
2022-06-30 1.904 -55.923 -62.644
2022-03-31 1.998 -53.699 -61.287
2021-12-31 1.754 -52.198 -60.561
2021-09-30 1.162 -49.026 -60.06
2021-06-30 0.246 -43.407 -57.266

SYBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SYBX has a Quality Grade of C, ranking ahead of 35.88% of graded US stocks.
  • SYBX's asset turnover comes in at 0.002 -- ranking 425th of 681 Pharmaceutical Products stocks.
  • RMTI, FATE, and FBRX are the stocks whose asset turnover ratios are most correlated with SYBX.

The table below shows SYBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.437
2021-03-31 0.003 1 -0.440
2020-12-31 0.004 1 -0.412
2020-09-30 0.011 1 -0.366
2020-06-30 0.012 1 -0.338
2020-03-31 0.010 1 -0.291

SYBX Price Target

For more insight on analysts targets of SYBX, see our SYBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.42 (Moderate Buy)

Synlogic, Inc. (SYBX) Company Bio


Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SYBX Latest News Stream


Event/Time News Detail
Loading, please wait...

SYBX Latest Social Stream


Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about SYNLOGIC INC that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic Announces Contract with the Air Force Research Lab

- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to

Yahoo | December 27, 2023

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), includin

Yahoo | December 7, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

Yahoo | November 14, 2023

Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ...

Key Developments and Financial Highlights for Investors

Yahoo | November 9, 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enrollment completion in 2024, with top-line data in the first half of 2025 - - Company received Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) as a potential treatment for PKU - CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlo

Yahoo | November 9, 2023

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo -40.50%
3-mo -4.50%
6-mo -73.96%
1-year -83.02%
3-year -96.84%
5-year -98.61%
YTD -50.39%
2023 -66.23%
2022 -68.60%
2021 12.04%
2020 -16.28%
2019 -63.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!